News
Alexander I. Spira, MD, PhD, of The US Oncology Network, discusses findings from the COCOON trial that show prophylactic ...
Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease ...
The FDA has approved garadacimab-gxii for prophylactic use in patients aged 12 years and older with hereditary angioedema, ...
The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...
Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with hemophilia A in new phase 3 data presented at the ISTH 2025 Congress Mim8 prophylaxis treatment ...
A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific ...
New FRONTIER5 results show a direct switch to investigational Mim8 (denecimig) prophylaxis treatment from emicizumab, without the need for a washout period, was well-tolerated in adults and ...
Novo Nordisk today presented results from the phase 3b FRONTIER5 trial showing that a direct switch to investigational Mim8 (denecimig) prophylaxis from emicizumab treatment, without a washout ...
The FRONTIER clinical programme investigates Mim8 as a prophylaxis treatment for people with haemophilia A, with or without inhibitors. This programme includes FRONTIER1, FRONTIER2, FRONTIER3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results